Bacterial flavoprotein oxidoreductases and monoamine oxidase

Bacterial flavoprotein oxidoreductases and human monoamine oxidases (MAO) represent two distinct classes of enzymes that utilize flavin cofactors, such as flavin adenine dinucleotide (FAD), to catalyze essential redox reactions (Source: PubMed PMID 21234351). Bacterial flavoprotein oxidoreductases, including nitroreductases, are critical for microbial metabolism and serve as therapeutic targets for the activation of nitroheterocyclic prodrugs like metronidazole and nitrofurantoin, which generate cytotoxic radicals upon reduction to damage bacterial DNA (Source: PubMed PMID 15591134). In humans, monoamine oxidases (MAO-A and MAO-B) are mitochondrial enzymes responsible for the oxidative deamination of biogenic amines, such as serotonin, dopamine, and norepinephrine (Source: UniProt P21397, P27338). MAO inhibitors (MAOIs) are clinically significant for treating major depressive disorder and Parkinson's disease by increasing the availability of these neurotransmitters in the central nervous system (Source: StatPearls NBK539848). While both enzyme groups share a reliance on flavin chemistry, they are biologically and therapeutically distinct, with bacterial enzymes serving as antibiotic targets and human MAOs serving as neuropsychiatric targets. The combination of these two categories into a single target entry is technically incorrect as they represent different organisms and physiological pathways.

Other names

FlavoenzymesFlavin-dependent oxidoreductasesMonoamine oxidase (MAO)Bacterial nitroreductase

Inhibition of oxidative deamination of biogenic amines (MAO) and reductive activation of nitro-group containing antibiotics (Bacterial oxidoreductases).